ArticleScientific reports2022
Polypharmacy and risk of mortality among patients with heart failure following hospitalization: a nested case-control study.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Cardiovascular risk associated with polypharmacy in heart failure: a systematic review and meta-analysis.ESC heart failure · 2026Pooled it
- Assessing Associations of Three Types of Higher-Risk Medication Use and Mortality in Older Adults.Journal of the American Geriatrics Society · 2026Article
- Prognostic effect of polypharmacy in ambulatory patients with heart failure: a machine learning-based analysis.BMC cardiovascular disorders · 2026Article
- Influence of drugs on blood potassium levels in older, multi-medicated patients - results of two cohort studies focusing on adverse drug reactions.BMC geriatrics · 2026Article
- Life-Space Mobility in Heart Failure With Preserved Ejection Fraction.Journal of cardiac failure - intersections · 2026Article
- The association between polypharmacy and mortality in patients with heart failure: Results from the PULSE dataset.ESC heart failure · 2025Observational
- Polypill in heart failure: a pathway to simplified treatment and improved adherence and outcomes.Heart failure reviews · 2025Review
- Geriatric Vulnerabilities Among Adults With Heart Failure With Preserved Ejection Fraction: A Cross-Continent Evaluation.JACC. Advances · 2025Article
- Polypharmacy Prevalence Among Older Adults Based on the Survey of Health, Ageing and Retirement in Europe: An Update.Journal of clinical medicine · 2025Article
- A Defined, Plant-Based Diet and Other Integrative Therapies Improve Functional Status and Ejection Fraction while Reducing Medications in Patients With Heart Failure: A Case Series.American journal of lifestyle medicine · 2024Article
- Impact of SGLT2 Inhibitors on Very Elderly Population with Heart Failure with Reduce Ejection Fraction: Real Life Data.Biomedicines · 2024Article
- The association between continuous polypharmacy and hospitalization, emergency department visits, and death in older adults: a nationwide large cohort study.Frontiers in pharmacology · 2024Article
- Prevalence of polypharmacy in heart failure patients: A retrospective cross-sectional study in a tertiary hospital in Saudi Arabia.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Development and validation of a prediction model for in-hospital death in patients with heart failure and atrial fibrillation.BMC cardiovascular disorders · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is associated with morbidity, rehospitalization and polypharmacy. The incidence rate of mortality in HF patients with polypharmacy is poorly studied. We examine the association of polypharmacy with mortality risk in incident hospitalized HF patients with a primary diagnosis after discharge from the hospital using Quebec administrative databases, Canada from 1999 to 2015. Polypharmacy, cardiovascular (CV) polypharmacy and non-CV polypharmacy were respectively defined as exposure to ≥ 10 drugs, ≥ 5 CV drugs and ≥ 5 non-CV drugs within three months prior to the case or the control selection date. We conducted a nested case-control study to estimate rate ratios (RR) of all-cause mortality using a multivariate conditional logistic regression during one-year of follow-up. We identified 12,242 HF patients with a mean age of 81.6 years. Neither CV polypharmacy (RR 0.97, 95%CI 0.82-1.15) nor non-CV polypharmacy (RR 0.93, 95%CI 0.77-1.12) were associated with lower mortality risk. However, all polypharmacy (RR 1.31, 95%CI 1.07-1.61) showed an association with mortality risk. Myocardial infarction, valvular disease, peripheral artery disease, diabetes, major bleeding, chronic kidney disease, high comorbidity score, high Frailty score, hydralazine and spironolactone users were associated with increasing mortality risk, ranging from 15 to 61%, while use of angiotensin II inhibitors, beta-blockers, statins, anticoagulant, and antiplatelets were associated with lower risk, ranging from 23 to 32%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.